Spinogenix Announces World Health Organization Approval of ‘tazbentetol’ as International Non-Proprietary Name for SPG302
Tazbentetol is a First-in-Class, Synaptic Regenerative Investigation Therapy for Alzheimer's disease, ALS, Schizophrenia and Glaucoma Spinogenix, Inc., a clinical-stage pharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization approved 'tazbentetol'as the non-proprietary name of […]